Press Information Bureau
Government of India
Ministry of Commerce & Industry
25-April-2016 18:06 IST
IPR Issues

India continues to be placed on the Priority Watch List under the US Special 301 on account of USA’s assessment of Indian IPR protection being inadequate. The Special 301 Report issued by the United States under their Trade Act of 1974 is a unilateral measure to create pressure on countries to enhance IPR protection beyond the TRIPS agreement. Under the WTO regime, any dispute between two countries needs to be referred to the Dispute Settlement Body of the WTO and unilateral actions are not tenable under this regime. Special 301 which is an extra territorial application of the domestic law of a country is inconsistent with the established norms of the WTO.

The government is committed to fully utilizing all the flexibilities provided under the TRIPS agreement to protect domestic pharmaceutical sector from pressure exerted by the foreign countries. In this regard, it is also to be mentioned that FDI is permitted in the brownfield Pharma sector through government approval route only.

This information was given by the Minister of State (Independent Charge) in the Ministry of Commerce & Industry Smt. Nirmala Sitharaman in a written reply in Lok Sabha today.